High Point, North Carolina (June 15, 2015)
vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its Class A common stock.
Piper Jaffray & Co. and Stifel are acting as joint book running managers for the offering. Canaccord Genuity and Janney Montgomery Scott will act as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.
This offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained by contacting: Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About vTv Therapeutics LLC
vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Contacts:
Investors
The Trout Group
Marc Panoff
646-378-2958
mpanoff@troutgroup.com
Media
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com